Clinical development

Top 10 rare disease pharma sees 10.4% rise in therapy start

Top 10 rare disease pharma sees 10.4% rise in therapy start

By Liza Laws

A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and personalized communications.

FDA lifts partial clinical hold on phase 3 low blood sugar treatment

FDA lifts partial clinical hold on phase 3 low blood sugar treatment

By Larissa Worneck-Silvestrin

Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a novel therapy in development for the treatment of low blood sugar (hypoglycemia) resulting from congenital hyperinsulinism.